TCGA-55-7913, TCGA-55-7913SENT_1,"LUNG CANCER MUTATION PANEL SPECIMEN SOURCE : LEFT LOWER LOBF l IING SPECIMENIBLOCK NUMBER EGFR Mutation : NOT DETECTED This result was reviewed and interpreted by The foilowing polymorphism was detected : 2361g > A. Sequencing of the entire coding region and splice junction sites of exons 18-21 of the EGFR gene revealed no previously published mutations or any sequence changes that could result in amino acid changes .","{LUNG,CANCER,MUTATION,PANEL,SPECIMEN,SOURCE,:,LEFT,LOWER,LOBF,l,IING,SPECIMENIBLOCK,NUMBER,EGFR,Mutation,:,NOT,DETECTED,This,result,was,reviewed,and,interpreted,by,The,foilowing,polymorphism,was,detected,:,2361g,>,A.,Sequencing,of,the,entire,coding,region,and,splice,junction,sites,of,exons,18-21,of,the,EGFR,gene,revealed,no,previously,published,mutations,or,any,sequence,changes,that,could,result,in,amino,acid,changes,.}","{lung,CANCER,MUTATION,PANEL,SPECIMEN,SOURCE,:,LEFT,LOWER,LOBF,l,IING,SPECIMENIBLOCK,NUMBER,egfr,mutation,:,not,detect,this,result,be,review,and,interpret,by,the,foilowing,polymorphism,be,detect,:,2361g,>,a.,sequencing,of,the,entire,coding,region,and,splice,junction,site,of,exon,18-21,of,the,egfr,gene,reveal,no,previously,publish,mutation,or,any,sequence,change,that,could,result,in,amino,acid,change,.}","{NN,NNP,NNP,NNP,NNP,NNP,:,NNP,NNP,NNP,NN,NNP,NNP,NNP,NN,NN,:,NN,VBD,DT,NN,VBD,VBN,CC,VBN,IN,DT,NN,NN,VBD,VBN,:,JJ,JJR,NN,NN,IN,DT,JJ,NN,NN,CC,NN,NN,NNS,IN,NNS,CD,IN,DT,NN,NN,VBD,DT,RB,VBN,NNS,CC,DT,NN,NNS,WDT,MD,VB,IN,NN,NN,NNS,.}","{19,6,6,6,6,1,0,10,10,1,10,16,16,16,16,11,0,19,0,21,25,23,19,0,19,0,29,29,23,31,29,0,36,36,36,19,0,41,41,41,36,0,45,45,53,0,45,47,0,52,52,47,19,57,56,57,53,0,61,61,57,64,64,61,0,68,68,64,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_2,"However one or more polymorphic sequence changes were discovered in the EGFR gene .","{However,one,or,more,polymorphic,sequence,changes,were,discovered,in,the,EGFR,gene,.}","{however,one,or,more,polymorphic,sequence,change,be,discover,in,the,egfr,gene,.}","{RB,CD,CC,JJR,JJ,NN,NNS,VBD,VBN,IN,DT,NN,NN,.}","{10,8,0,8,8,8,10,10,0,0,14,14,10,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_3,"These polymorphisms are interpreted as non-pathogenic because they do not lead to amino acid changes .","{These,polymorphisms,are,interpreted,as,non-pathogenic,because,they,do,not,lead,to,amino,acid,changes,.}","{these,polymorphism,be,interpret,as,non-pathogenic,because,they,do,not,lead,to,amino,acid,change,.}","{DT,NNS,VBP,VBN,IN,JJ,IN,PRP,VBP,RB,VB,TO,NN,NN,NNS,.}","{2,4,4,0,0,4,11,11,11,11,4,0,15,15,11,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_4,"These polymorphisms are not expected to have any clinical signi?cance .","{These,polymorphisms,are,not,expected,to,have,any,clinical,signi?cance,.}","{these,polymorphism,be,not,expect,to,have,any,clinical,signi?cance,.}","{DT,NNS,VBP,RB,VBN,TO,VB,DT,JJ,NN,.}","{2,5,5,5,0,7,5,10,10,7,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_5,"As 7 % of patients who respond to EGFR inhibitors do not show mutations in exons 18-21 of EGFR gene a negative resutt does not preclude the possibility of a clinical response to EGFR inhibitors .","{As,7,%,of,patients,who,respond,to,EGFR,inhibitors,do,not,show,mutations,in,exons,18-21,of,EGFR,gene,a,negative,resutt,does,not,preclude,the,possibility,of,a,clinical,response,to,EGFR,inhibitors,.}","{as,7,%,of,patient,who,respond,to,egfr,inhibitor,do,not,show,mutation,in,exon,18-21,of,egfr,gene,a,negative,resutt,do,not,preclude,the,possibility,of,a,clinical,response,to,egfr,inhibitor,.}","{IN,CD,NN,IN,NNS,WP,VBP,TO,NN,NNS,VBP,RB,VB,NNS,IN,NNS,CD,IN,NN,NN,DT,JJ,NN,VBZ,RB,VB,DT,NN,IN,DT,JJ,NN,TO,NN,NNS,.}","{13,3,13,0,3,7,5,0,10,7,13,13,27,13,0,13,16,0,20,16,24,24,27,27,27,0,29,27,0,33,33,29,0,36,27,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_6,"KRAS Mutation Analysis KRAS Mutation : NOT DETECTED Based on sequence analysis no mutations were detected in K-Ras exon 1 ( codon 12 & 13 ) and exon 2 ( codon 51 ) This result was reviewed and interpreted by FISH ALK .","{KRAS,Mutation,Analysis,KRAS,Mutation,:,NOT,DETECTED,Based,on,sequence,analysis,no,mutations,were,detected,in,K-Ras,exon,1,(,codon,12,&,13,),and,exon,2,(,codon,51,),This,result,was,reviewed,and,interpreted,by,FISH,ALK,.}","{KRAS,mutation,analysis,KRAS,mutation,:,not,detect,base,on,sequence,analysis,no,mutation,be,detect,in,k-ras,exon,1,(,codon,12,&,13,),and,exon,2,(,codon,51,),this,result,be,review,and,interpret,by,fish,alk,.}","{NNP,NN,NN,NNP,NN,:,NN,VBD,VBN,IN,NN,NN,DT,NNS,VBD,VBN,IN,JJ,NN,CD,NN,NN,CD,CC,CD,NN,CC,NN,CD,CD,NN,CD,NN,DT,NN,VBD,VBN,CC,VBN,IN,NN,NN,.}","{3,3,38,5,8,0,5,38,0,17,12,17,15,17,17,8,0,20,17,23,23,17,23,0,27,23,0,23,29,34,34,34,8,36,38,38,0,0,38,0,43,38,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_7,"2923 FISH ALK .","{2923,FISH,ALK,.}","{2923,fish,ALK,.}","{CD,NN,NNP,.}","{2,0,2,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_8,"ZP23 ; SEE BELOW Specimen Type : Paraf?n Embedded Tumor Tissue Clinical Indication : FISH study for oncology Method : FESH Total Cells : 100 Images Captured : 2 RESULT :","{ZP23,;,SEE,BELOW,Specimen,Type,:,Paraf?n,Embedded,Tumor,Tissue,Clinical,Indication,:,FISH,study,for,oncology,Method,:,FESH,Total,Cells,:,100,Images,Captured,:,2,RESULT,:}","{zp23,;,see,below,Specimen,type,:,Paraf?n,embed,tumor,tissue,clinical,indication,:,fish,study,for,oncology,Method,:,FESH,Total,cell,:,100,image,capture,:,2,result,:}","{NN,:,VB,IN,NNP,NN,:,NNP,VBD,NN,NN,JJ,NN,:,NN,NN,IN,JJ,NNP,:,NNP,NNP,NNS,:,CD,NNS,VBN,:,CD,NN,:}","{0,0,1,0,6,3,0,9,3,11,9,13,11,0,16,11,0,19,16,0,22,11,22,0,26,11,26,0,11,29,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_9,"INTERPRETATION : FISH RESULT NEGATIVE FOR REARRANGEMENT OF ALK GENE SUGGESTIVE OF GAIN OF ALK REGION .","{INTERPRETATION,:,FISH,RESULT,NEGATIVE,FOR,REARRANGEMENT,OF,ALK,GENE,SUGGESTIVE,OF,GAIN,OF,ALK,REGION,.}","{interpretation,:,fish,RESULT,NEGATIVE,for,REARRANGEMENT,of,ALK,GENE,SUGGESTIVE,of,GAIN,of,ALK,REGION,.}","{NN,:,NN,NNP,NNP,IN,NNP,IN,NNP,NNP,NNP,IN,NNP,IN,NNP,NNP,.}","{0,0,5,5,1,0,5,0,10,7,10,0,12,0,17,14,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_10,"Fluorescence in ? situ hybridization ( FISH ) analysis using break-apart probes speci?c for ALK gene ( 2p23 ; Abbott Motecular ) did not exhibit a break ~ apart pattern .","{Fluorescence,in,?,situ,hybridization,(,FISH,),analysis,using,break-apart,probes,speci?c,for,ALK,gene,(,2p23,;,Abbott,Motecular,),did,not,exhibit,a,break,~,apart,pattern,.}","{fluorescence,in,?,situ,hybridization,(,fish,),analysis,use,break-apart,probe,speci?c,for,alk,gene,(,2p23,;,Abbott,Motecular,),do,not,exhibit,a,break,~,apart,pattern,.}","{NN,IN,FW,FW,NN,CD,NN,NN,NN,VBG,JJ,NNS,VBP,IN,NN,NN,CD,NN,:,NNP,NNP,NN,VBD,RB,VB,DT,NN,NN,RB,NN,.}","{27,0,5,5,1,9,9,9,5,27,13,14,11,0,17,14,19,17,0,22,17,22,27,27,0,30,30,27,27,31,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_11,"Thus this result is not indicative of a translocation involving the ALK gene .","{Thus,this,result,is,not,indicative,of,a,translocation,involving,the,ALK,gene,.}","{thus,this,result,be,not,indicative,of,a,translocation,involve,the,alk,gene,.}","{RB,DT,NN,VBZ,RB,JJ,IN,DT,NN,VBG,DT,NN,NN,.}","{7,4,7,7,7,0,0,10,7,10,14,14,11,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_12,"As an incidental ?nding additional 1-6 copies ofthe ALK region were observed in 79 % of cells .","{As,an,incidental,?nding,additional,1-6,copies,ofthe,ALK,region,were,observed,in,79,%,of,cells,.}","{as,a,incidental,?nding,additional,1-6,copy,ofthe,alk,region,be,observe,in,79,%,of,cell,.}","{IN,DT,JJ,NN,JJ,JJ,NNS,VBP,NN,NN,VBD,VBN,IN,CD,NN,IN,NNS,.}","{0,4,4,9,8,8,9,0,11,13,13,9,0,16,13,0,16,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_13,"This suggests gain of the ALK region .","{This,suggests,gain,of,the,ALK,region,.}","{this,suggest,gain,of,the,alk,region,.}","{DT,VBZ,NN,IN,DT,NN,NN,.}","{2,0,2,0,7,7,3,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_14,"The clinical signi?cance of this incidental ?nding is unknown .","{The,clinical,signi?cance,of,this,incidental,?nding,is,unknown,.}","{the,clinical,signi?cance,of,this,incidental,?nding,be,unknown,.}","{DT,JJ,NN,IN,DT,JJ,NN,VBZ,JJ,.}","{3,3,9,0,7,7,3,9,0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_15,"A small proportion of tumors ( approximately 5 % ) with ALK rearrangement demonstrated by other methods may be missed by this study .","{A,small,proportion,of,tumors,(,approximately,5,%,),with,ALK,rearrangement,demonstrated,by,other,methods,may,be,missed,by,this,study,.}","{a,small,proportion,of,tumor,(,approximately,5,%,),with,alk,rearrangement,demonstrate,by,other,method,may,be,miss,by,this,study,.}","{DT,JJ,NN,IN,NNS,CD,RB,CD,NN,CD,IN,NN,NN,VBN,IN,JJ,NNS,MD,VB,VBN,IN,DT,NN,.}","{3,3,20,0,3,7,20,9,7,20,0,13,10,13,0,17,14,20,20,0,0,23,20,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_16,"This result does not rule out a malignancy or other genetic changes .","{This,result,does,not,rule,out,a,malignancy,or,other,genetic,changes,.}","{this,result,do,not,rule,out,a,malignancy,or,other,genetic,change,.}","{DT,NN,VBZ,RB,VB,RP,DT,NN,CC,JJ,JJ,NNS,.}","{2,5,5,5,0,5,8,5,0,12,12,5,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_17,"This resuit should be considered in combination with other clinical andlor laboratory data .","{This,resuit,should,be,considered,in,combination,with,other,clinical,andlor,laboratory,data,.}","{this,resuit,should,be,consider,in,combination,with,other,clinical,andlor,laboratory,datum,.}","{DT,NN,MD,VB,VBN,IN,NN,IN,JJ,JJ,NN,NN,NNS,.}","{2,5,5,5,0,0,5,0,13,13,13,13,5,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_18,"The cutoff values for ALK rearrangement are 12 % for paraf?n-embedded specimens 3 % for bone marrow 5 % for peripheral blood .","{The,cutoff,values,for,ALK,rearrangement,are,12,%,for,paraf?n-embedded,specimens,3,%,for,bone,marrow,5,%,for,peripheral,blood,.}","{the,cutoff,value,for,ALK,rearrangement,be,12,%,for,paraf?n-embedded,specimen,3,%,for,bone,marrow,5,%,for,peripheral,blood,.}","{DT,NN,NNS,IN,NNP,NN,VBP,CD,NN,IN,JJ,NNS,CD,NN,IN,NN,NN,CD,NN,IN,JJ,NN,.}","{3,3,9,0,6,3,9,9,0,0,12,9,15,9,0,18,15,21,9,0,24,21,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_19,"Please expect the result of any other concurrent test in a separate report .","{Please,expect,the,result,of,any,other,concurrent,test,in,a,separate,report,.}","{please,expect,the,result,of,any,other,concurrent,test,in,a,separate,report,.}","{VB,VB,DT,NN,IN,DT,JJ,JJ,NN,IN,DT,JJ,NN,.}","{2,0,4,2,0,9,9,9,4,0,13,13,9,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_20,"This test was developed and its performance characteristics were determined by ) _ not been cleared or approved by the U.S. Food and Drug Administration .","{This,test,was,developed,and,its,performance,characteristics,were,determined,by,),_,not,been,cleared,or,approved,by,the,U.S.,Food,and,Drug,Administration,.}","{this,test,be,develop,and,its,performance,characteristic,be,determine,by,),_,not,be,clear,or,approve,by,the,U.S.,Food,and,Drug,Administration,.}","{DT,NN,VBD,VBN,CC,PRP$,NN,NNS,VBD,VBN,IN,CD,CD,RB,VBN,VBN,CC,VBN,IN,DT,NNP,NNP,CC,NNP,NNP,.}","{2,4,4,0,0,8,8,10,10,4,0,13,10,16,16,13,0,13,0,22,22,18,0,25,18,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_21,"The FDA has determined that such clearance or a rovalris not necessa l-rerformance characteristics refer to the analytical performance of the test .","{The,FDA,has,determined,that,such,clearance,or,a,rovalris,not,necessa,l-rerformance,characteristics,refer,to,the,analytical,performance,of,the,test,.}","{the,FDA,have,determine,that,such,clearance,or,a,rovalri,not,necessa,l-rerformance,characteristic,refer,to,the,analytical,performance,of,the,test,.}","{DT,NNP,VBZ,VBN,IN,JJ,NN,CC,DT,NN,RB,JJ,NN,NNS,VBP,TO,DT,JJ,NN,IN,DT,NN,.}","{2,4,4,0,15,7,15,0,10,11,7,14,14,7,4,0,19,19,15,0,22,19,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_22,"Laboratory results reviewed and Clinical interpretation provided by","{Laboratory,results,reviewed,and,Clinical,interpretation,provided,by}","{laboratory,result,review,and,clinical,interpretation,provide,by}","{NN,VBZ,VBN,CC,JJ,NN,VBN,IN}","{2,0,2,0,6,2,6,7}","{}"
TCGA-55-7913, TCGA-55-7913SENT_23,"Mutational analysis ofthe EGFR and KRAS genes and ALK locus rearrangement by FISH were perfonned to survey the most common tumor-associated genetic changes that have been shown to have prognostic and therapeutic consequences in non-small cell lung cancer ( NSCLC ) .","{Mutational,analysis,ofthe,EGFR,and,KRAS,genes,and,ALK,locus,rearrangement,by,FISH,were,perfonned,to,survey,the,most,common,tumor-associated,genetic,changes,that,have,been,shown,to,have,prognostic,and,therapeutic,consequences,in,non-small,cell,lung,cancer,(,NSCLC,),.}","{mutational,analysis,ofthe,egfr,and,kra,gene,and,alk,locus,rearrangement,by,fish,be,perfonn,to,survey,the,most,common,tumor-associated,genetic,change,that,have,be,show,to,have,prognostic,and,therapeutic,consequence,in,non-small,cell,lung,cancer,(,nsclc,),.}","{JJ,NN,JJ,NN,CC,NN,NNS,CC,NN,NN,NN,IN,NN,VBD,VBN,TO,VB,DT,RBS,JJ,JJ,JJ,NNS,WDT,VBP,VBN,VBN,TO,VB,JJ,CC,JJ,NNS,IN,JJ,NN,NN,NN,CD,NN,NN,.}","{4,4,4,15,0,7,15,0,11,11,4,0,11,15,0,17,15,23,20,23,23,23,17,27,27,27,23,29,27,33,0,33,29,0,37,37,33,41,41,41,37,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_24,"EGFR kinase domain mutations are found in 10-15 % of lung adenocarcinomas particularly those occurring in younger patients without a smoking history and identify tumors that may have signi?cant clinical response to EGFR-targeted kinase inhibitors .","{EGFR,kinase,domain,mutations,are,found,in,10-15,%,of,lung,adenocarcinomas,particularly,those,occurring,in,younger,patients,without,a,smoking,history,and,identify,tumors,that,may,have,signi?cant,clinical,response,to,EGFR-targeted,kinase,inhibitors,.}","{egfr,kinase,domain,mutation,be,find,in,10-15,%,of,lung,adenocarcinoma,particularly,those,occur,in,younger,patient,without,a,smoking,history,and,identify,tumor,that,may,have,signi?cant,clinical,response,to,egfr-targeted,kinase,inhibitor,.}","{NN,NN,NN,NNS,VBP,VBN,IN,CD,NN,IN,NN,NNS,RB,DT,VBG,IN,JJR,NNS,IN,DT,NN,NN,CC,VB,NNS,WDT,MD,VB,JJ,JJ,NN,TO,JJ,NN,NNS,.}","{4,4,4,26,6,0,0,9,6,0,12,9,9,9,15,0,19,16,0,23,23,16,0,6,26,30,30,27,33,33,30,0,37,37,30,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_25,"Secondary somatic mutations in EGFR particularly TYQDM in exon 20 may accompany acquired resistance to these inhibitors .","{Secondary,somatic,mutations,in,EGFR,particularly,TYQDM,in,exon,20,may,accompany,acquired,resistance,to,these,inhibitors,.}","{secondary,somatic,mutation,in,egfr,particularly,TYQDM,in,exon,20,may,accompany,acquire,resistance,to,these,inhibitor,.}","{JJ,JJ,NNS,IN,NN,RB,NNP,IN,NN,CD,MD,VB,VBN,NN,TO,DT,NNS,.}","{3,3,14,0,3,3,3,0,8,10,14,0,16,14,0,19,14,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_26,"KRAS point mutations occur in 20-30 % of lung adenocarcinomas and are largely mutually exclusive with EGFR mutations .","{KRAS,point,mutations,occur,in,20-30,%,of,lung,adenocarcinomas,and,are,largely,mutually,exclusive,with,EGFR,mutations,.}","{KRAS,point,mutation,occur,in,20-30,%,of,lung,adenocarcinoma,and,be,largely,mutually,exclusive,with,egfr,mutation,.}","{NNP,NN,NNS,VBP,IN,CD,NN,IN,NN,NNS,CC,VBP,RB,RB,JJ,IN,NN,NNS,.}","{3,3,15,0,0,7,4,0,10,7,0,15,15,15,4,0,18,15,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_27,"KRAS mutations are associated with a poor prognosis and resistance to anti-EGFR-directed lmmunotherapy .","{KRAS,mutations,are,associated,with,a,poor,prognosis,and,resistance,to,anti-EGFR-directed,lmmunotherapy,.}","{KRAS,mutation,be,associate,with,a,poor,prognosis,and,resistance,to,anti-egfr-directed,lmmunotherapy,.}","{NNP,NNS,VBP,VBN,IN,DT,JJ,NN,CC,NN,TO,JJ,NN,.}","{2,4,4,0,0,8,8,4,0,4,0,13,8,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_28,"ALK locus rearrangement resulting in the EML4-ALK gene fusion is present in 3-5 % of NSCLC is most commonly seen in adenocarcinomas from younger patients and produces overexpression of the ALK tyrosine kinase .","{ALK,locus,rearrangement,resulting,in,the,EML4-ALK,gene,fusion,is,present,in,3-5,%,of,NSCLC,is,most,commonly,seen,in,adenocarcinomas,from,younger,patients,and,produces,overexpression,of,the,ALK,tyrosine,kinase,.}","{alk,locus,rearrangement,result,in,the,eml4-alk,gene,fusion,be,present,in,3-5,%,of,NSCLC,be,most,commonly,see,in,adenocarcinoma,from,younger,patient,and,produce,overexpression,of,the,ALK,tyrosine,kinase,.}","{NN,NN,NN,VBG,IN,DT,NN,NN,NN,VBZ,JJ,IN,CD,NN,IN,NNP,VBZ,RBS,RB,VBN,IN,NNS,IN,JJR,NNS,CC,VBZ,NN,IN,DT,NNP,NN,NN,.}","{3,3,29,3,0,9,9,9,4,11,0,0,14,11,0,14,21,20,21,11,0,21,0,26,23,0,11,29,0,35,35,35,30,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_29,"Patients who harbor ALK rearrangement do not bene?t from EGF R tyrosine kinase inhibitors and are recommended to be directed to trials of ALK-targeted agents .","{Patients,who,harbor,ALK,rearrangement,do,not,bene?t,from,EGF,R,tyrosine,kinase,inhibitors,and,are,recommended,to,be,directed,to,trials,of,ALK-targeted,agents,.}","{patient,who,harbor,alk,rearrangement,do,not,bene?t,from,egf,r,tyrosine,kinase,inhibitor,and,be,recommend,to,be,direct,to,trial,of,alk-targeted,agent,.}","{NNS,WP,VBP,NN,NN,VBP,RB,VBN,IN,NN,NN,NN,NN,NNS,CC,VBP,VBN,TO,VB,VBN,TO,NNS,IN,JJ,NNS,.}","{17,3,1,5,3,0,8,6,0,14,14,14,14,8,0,17,6,20,20,17,0,20,0,25,22,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_30,"The exons tested cumulatively comprise greater than 95 % of the known activating mutations in the selected genes ; rare mutations occurring at other sites or in other genes that may in?uence outcome can not be excluded .","{The,exons,tested,cumulatively,comprise,greater,than,95,%,of,the,known,activating,mutations,in,the,selected,genes,;,rare,mutations,occurring,at,other,sites,or,in,other,genes,that,may,in?uence,outcome,can,not,be,excluded,.}","{the,exon,test,cumulatively,comprise,greater,than,95,%,of,the,known,activating,mutation,in,the,select,gene,;,rare,mutation,occur,at,other,site,or,in,other,gene,that,may,in?uence,outcome,can,not,be,exclude,.}","{DT,NNS,VBN,RB,VBP,JJR,IN,CD,NN,IN,DT,JJ,NN,NNS,IN,DT,VBN,NNS,:,JJ,NNS,VBG,IN,JJ,NNS,CC,IN,JJ,NNS,WDT,MD,VB,NN,MD,RB,VB,VBN,.}","{2,5,2,3,0,7,8,9,5,0,14,14,14,9,0,18,18,5,0,21,37,21,0,25,22,0,0,29,22,32,32,29,32,37,37,37,5,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_31,"Genomic DNA was extracted from microdissected paratlin ? embedded tissue sections isolated from the submitted block .","{Genomic,DNA,was,extracted,from,microdissected,paratlin,?,embedded,tissue,sections,isolated,from,the,submitted,block,.}","{genomic,dna,be,extract,from,microdissected,paratlin,?,embedded,tissue,section,isolate,from,the,submit,block,.}","{JJ,NN,VBD,VBN,IN,JJ,NN,NN,JJ,NN,NNS,VBN,IN,DT,VBN,NN,.}","{2,4,4,0,0,8,8,4,11,11,4,11,0,16,16,12,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_32,"PCR-based DNA sequencing was used to assess for mutations in exon 1 ( including codon 12 8 .","{PCR-based,DNA,sequencing,was,used,to,assess,for,mutations,in,exon,1,(,including,codon,12,8,.}","{pcr-based,dna,sequencing,be,use,to,assess,for,mutation,in,exon,1,(,include,codon,12,8,.}","{JJ,NN,NN,VBD,VBN,TO,VB,IN,NNS,IN,NN,CD,CD,VBG,NN,CD,CD,.}","{3,3,5,5,0,7,5,0,7,0,9,13,7,0,13,17,15,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_33,"13 ) and exon 2 ( including codon 61 ) of KRAS and exons 18-21 of the EGFR tyrosine kinase ( TK ) domain .","{13,),and,exon,2,(,including,codon,61,),of,KRAS,and,exons,18-21,of,the,EGFR,tyrosine,kinase,(,TK,),domain,.}","{13,),and,exon,2,(,include,codon,61,),of,KRAS,and,exon,18-21,of,the,egfr,tyrosine,kinase,(,tk,),domain,.}","{CD,NN,CC,NN,CD,CD,VBG,NN,CD,NN,IN,NNP,CC,NNS,CD,IN,DT,NN,NN,NN,CD,NN,NN,NN,.}","{2,6,0,2,6,0,0,10,10,6,0,10,14,6,14,0,20,20,20,14,24,24,24,14,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_34,"The sensitivity for mutation detection for these assays is approximately 10 % mutant allele in the background of normal allele in the microdissected area .","{The,sensitivity,for,mutation,detection,for,these,assays,is,approximately,10,%,mutant,allele,in,the,background,of,normal,allele,in,the,microdissected,area,.}","{the,sensitivity,for,mutation,detection,for,these,assay,be,approximately,10,%,mutant,allele,in,the,background,of,normal,allele,in,the,microdissected,area,.}","{DT,NN,IN,NN,NN,IN,DT,NNS,VBZ,RB,CD,NN,JJ,NN,IN,DT,NN,IN,JJ,NN,IN,DT,JJ,NN,.}","{2,14,0,5,2,0,8,5,14,14,12,10,14,0,0,17,14,0,20,17,0,24,24,20,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_35,"The KRAS and EGFR test was developed and its performance characteristics have been detennined by Capistrano .","{The,KRAS,and,EGFR,test,was,developed,and,its,performance,characteristics,have,been,detennined,by,Capistrano,.}","{the,KRAS,and,egfr,test,be,develop,and,its,performance,characteristic,have,be,detennine,by,Capistrano,.}","{DT,NNP,CC,NN,NN,VBD,VBN,CC,PRP$,NN,NNS,VBP,VBN,VBN,IN,NNP,.}","{2,7,0,5,2,7,0,0,11,11,14,14,14,7,0,14,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_36,"Performance characteristics refer to the analytical performance of the test .","{Performance,characteristics,refer,to,the,analytical,performance,of,the,test,.}","{Performance,characteristic,refer,to,the,analytical,performance,of,the,test,.}","{NNP,NNS,VBP,TO,DT,JJ,NN,IN,DT,NN,.}","{2,3,0,0,7,7,3,0,10,7,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_37,"The FISH test was developed and its perfomtance characteristics have been determined by It has not been cleared or approved by the U.S. Food and Drug Administration .","{The,FISH,test,was,developed,and,its,perfomtance,characteristics,have,been,determined,by,It,has,not,been,cleared,or,approved,by,the,U.S.,Food,and,Drug,Administration,.}","{the,fish,test,be,develop,and,its,perfomtance,characteristic,have,be,determine,by,it,have,not,be,clear,or,approve,by,the,U.S.,Food,and,Drug,Administration,.}","{DT,NN,NN,VBD,VBN,CC,PRP$,NN,NNS,VBP,VBN,VBN,IN,PRP,VBZ,RB,VBN,VBN,CC,VBN,IN,DT,NNP,NNP,CC,NNP,NNP,.}","{3,3,5,5,0,0,9,9,12,12,12,5,0,20,18,18,18,12,0,18,0,24,24,18,0,27,18,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_38,"The FDA has determined that such clearance oriapproval is not necessary .","{The,FDA,has,determined,that,such,clearance,oriapproval,is,not,necessary,.}","{the,FDA,have,determine,that,such,clearance,oriapproval,be,not,necessary,.}","{DT,NNP,VBZ,VBN,IN,JJ,NN,NN,VBZ,RB,JJ,.}","{2,4,4,0,11,8,8,11,11,11,4,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_39,"Performance characteristics refer to the analytical perfonnance ofthe test .","{Performance,characteristics,refer,to,the,analytical,perfonnance,ofthe,test,.}","{Performance,characteristic,refer,to,the,analytical,perfonnance,ofthe,test,.}","{NNP,NNS,VBP,TO,DT,JJ,NN,NN,NN,.}","{2,3,0,0,9,9,9,9,3,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_40,"Test performed at I","{Test,performed,at,I}","{test,perform,at,I}","{NN,VBN,IN,PRP}","{2,0,0,2}","{}"
TCGA-55-7913, TCGA-55-7913SENT_41,"Addendum Report Issued By :","{Addendum,Report,Issued,By,:}","{Addendum,Report,issue,by,:}","{NNP,NNP,VBD,IN,:}","{2,3,0,3,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_42,"DIAGNOSIS : A. Left lower lobe lung lobectomy : Tumor Characteristics : 1 .","{DIAGNOSIS,:,A.,Left,lower,lobe,lung,lobectomy,:,Tumor,Characteristics,:,1,.}","{diagnosis,:,a.,leave,lower,lobe,lung,lobectomy,:,tumor,characteristic,:,1,.}","{NN,:,NN,VBD,JJR,NN,NN,NN,:,NN,NNS,:,CD,.}","{0,0,4,1,7,7,4,7,0,12,7,0,12,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_43,"Histologic type : Adenocarcinoma .","{Histologic,type,:,Adenocarcinoma,.}","{histologic,type,:,adenocarcinoma,.}","{JJ,NN,:,NN,.}","{2,0,0,2,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_44,"2 .","{2,.}","{2,.}","{LS,.}","{0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_45,"Histologic grade : Well differentiated with focal mucin production .","{Histologic,grade,:,Well,differentiated,with,focal,mucin,production,.}","{histologic,grade,:,well,differentiate,with,focal,mucin,production,.}","{JJ,NN,:,UH,VBN,IN,JJ,NN,NN,.}","{2,5,0,5,0,0,9,9,5,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_46,"3 .","{3,.}","{3,.}","{LS,.}","{0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_47,"Tumor site : Left lower lobe lung .","{Tumor,site,:,Left,lower,lobe,lung,.}","{tumor,site,:,leave,lower,lobe,lung,.}","{NN,NN,:,VBN,JJR,NN,NN,.}","{2,4,0,0,7,7,4,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_48,"Tumor focality : Unifocal .","{Tumor,focality,:,Unifocal,.}","{tumor,focality,:,Unifocal,.}","{NN,NN,:,NNP,.}","{2,0,0,2,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_49,"Tumor size : 2.8 x 2.7 x 2.4 cm .","{Tumor,size,:,2.8,x,2.7,x,2.4,cm,.}","{tumor,size,:,2.8,x,2.7,x,2.4,cm,.}","{NN,NN,:,CD,CC,CD,CC,CD,NN,.}","{2,0,0,2,0,4,0,9,6,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_50,"Visceral pleural invasion : No. .","{Visceral,pleural,invasion,:,No.,.}","{visceral,pleural,invasion,:,no.,.}","{JJ,JJ,NN,:,NN,.}","{3,3,0,0,3,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_51,"Lymphovascular space invasion : No. .","{Lymphovascular,space,invasion,:,No.,.}","{lymphovascular,space,invasion,:,no.,.}","{JJ,NN,NN,:,NN,.}","{3,3,0,0,3,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_52,"Tumor extension : Con?ned to the left lower lobe .","{Tumor,extension,:,Con?ned,to,the,left,lower,lobe,.}","{tumor,extension,:,con?ned,to,the,leave,lower,lobe,.}","{NN,NN,:,VBN,TO,DT,VBN,JJR,NN,.}","{2,4,0,0,0,4,6,9,7,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_53,".0 ? .","{.0,?,.}","{.0,?,.}","{NN,NN,.}","{0,1,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_54,"? 4F5 ? .","{?,4F5,?,.}","{?,4f5,?,.}","{NN,NN,NN,.}","{0,3,1,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_55,"U .","{U,.}","{U,.}","{NNP,.}","{2,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_56,"- l ?","{-,l,?}","{-,l,?}","{:,NN,CD}","{0,0,2}","{}"
TCGA-55-7913, TCGA-55-7913SENT_57,"Surgical Margin Status :","{Surgical,Margin,Status,:}","{Surgical,margin,Status,:}","{NNP,NN,NNP,:}","{3,3,0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_58,"1 .","{1,.}","{1,.}","{LS,.}","{0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_59,"Tumor distance from bronchial margin : o. ?","{Tumor,distance,from,bronchial,margin,:,o.,?}","{tumor,distance,from,bronchial,margin,:,o.,?}","{NN,NN,IN,JJ,NN,:,VB,.}","{2,3,7,5,3,0,0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_60,"? cm .","{?,cm,.}","{?,cm,.}","{NN,NN,.}","{0,1,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_61,"2 .","{2,.}","{2,.}","{LS,.}","{0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_62,"Tumor distance from parenchymal ( stapled ) margin : 0.5 cm .","{Tumor,distance,from,parenchymal,(,stapled,),margin,:,0.5,cm,.}","{tumor,distance,from,parenchymal,(,staple,),margin,:,0.5,cm,.}","{NN,NN,IN,JJ,NN,VBD,CD,NN,:,CD,NN,.}","{2,6,0,5,2,0,8,6,0,11,8,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_63,"3 .","{3,.}","{3,.}","{LS,.}","{0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_64,"Tumor distance from pleural surface : Adjacent to though does not involve the pleura .","{Tumor,distance,from,pleural,surface,:,Adjacent,to,though,does,not,involve,the,pleura,.}","{tumor,distance,from,pleural,surface,:,adjacent,to,though,do,not,involve,the,pleuron,.}","{NN,NN,IN,JJ,NN,:,JJ,TO,RB,VBZ,RB,VB,DT,NN,.}","{2,12,0,5,2,0,5,7,8,12,12,0,14,12,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_65,"TNM : pT1b","{TNM,:,pT1b}","{TNM,:,pt1b}","{NNP,:,NN}","{0,0,1}","{}"
TCGA-55-7913, TCGA-55-7913SENT_66,"13 .","{13,.}","{13,.}","{CD,.}","{0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_67,"Level 5 lymph node biopsies :","{Level,5,lymph,node,biopsies,:}","{level,5,lymph,node,biopsy,:}","{NN,CD,NN,NN,NNS,:}","{4,4,4,0,4,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_68,"Single node negative for malignancy ( 011 ) .","{Single,node,negative,for,malignancy,(,011,),.}","{single,node,negative,for,malignancy,(,011,),.}","{JJ,NN,JJ,IN,NN,NN,CD,NN,.}","{2,0,6,0,3,2,8,6,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_69,"O. Level 15 lymph node .","{O.,Level,15,lymph,node,.}","{O.,Level,15,lymph,node,.}","{NNP,NNP,CD,NN,NN,.}","{2,0,5,5,2,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_70,"biopsy :","{biopsy,:}","{biopsy,:}","{NN,:}","{0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_71,"Sinolelymph node nesativeformalignancy ( OH ) .","{Sinolelymph,node,nesativeformalignancy,(,OH,),.}","{sinolelymph,node,nesativeformalignancy,(,oh,),.}","{JJ,NN,NN,CD,NN,NN,.}","{3,3,0,6,6,3,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_72,"Y * _ Y * Y * __ __ @ Y * __ .","{Y,*,_,Y,*,Y,*,__,__,@,Y,*,__,.}","{y,*,_,y,*,y,*,__,__,@,y,*,__,.}","{NN,CD,CD,NN,CD,NN,CD,CD,NN,IN,NN,CD,NN,.}","{0,3,4,1,6,4,8,9,1,0,13,13,9,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_73,".","{.}","{.}","{.}","{0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_74,"_ ... : _ c _ : .","{_,...,:,_,c,_,:,.}","{_,...,:,_,c,_,:,.}","{NN,:,:,CD,NN,NN,:,.}","{0,0,0,6,4,1,0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_75,"s. $ .","{s.,$,.}","{s.,$,.}","{RB,$,.}","{0,1,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_76,".","{.}","{.}","{.}","{0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_77,"- L. .","{-,L.,.}","{-,l.,.}","{:,NN,.}","{0,0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_78,".","{.}","{.}","{.}","{0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_79,"_ .","{_,.}","{_,.}","{NN,.}","{0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_80,"COMMENTS : TTF1 by immunoperoxidase is positive consistent with a lung primary .","{COMMENTS,:,TTF1,by,immunoperoxidase,is,positive,consistent,with,a,lung,primary,.}","{comment,:,ttf1,by,immunoperoxidase,be,positive,consistent,with,a,lung,primary,.}","{NNS,:,NN,IN,NN,VBZ,JJ,JJ,IN,DT,NN,JJ,.}","{0,0,8,0,3,8,8,1,0,11,8,11,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_81,"Ancillary studies ( CLINICAL HISTORY : Preoperative Diagnosis Postoperative Diagnosi SymptomsfRadiologic Findings : SPECIMENS : A. Left lower lobe lung B. Level 9 lymph node C. Level5lymph node","{Ancillary,studies,(,CLINICAL,HISTORY,:,Preoperative,Diagnosis,Postoperative,Diagnosi,SymptomsfRadiologic,Findings,:,SPECIMENS,:,A.,Left,lower,lobe,lung,B.,Level,9,lymph,node,C.,Level5lymph,node}","{ancillary,study,(,clinical,history,:,Preoperative,diagnosis,postoperative,diagnosus,symptomsfradiologic,finding,:,specimen,:,a.,leave,lower,lobe,lung,B.,Level,9,lymph,node,C.,Level5lymph,node}","{JJ,NNS,VBP,JJ,NN,:,NNP,NN,JJ,NN,JJ,NNS,:,NNS,:,NN,VBD,JJR,NN,NN,NNP,NNP,CD,NN,NN,NNP,NNP,NN}","{2,3,17,5,3,0,5,10,10,3,12,10,0,10,0,14,0,19,22,22,22,17,26,26,26,22,28,17}","{}"
TCGA-55-7913, TCGA-55-7913SENT_82,"B. Container B is labeled le vel 9 lymph node .","{B.,Container,B,is,labeled,le,vel,9,lymph,node,.}","{B.,Container,b,be,label,le,vel,9,lymph,node,.}","{NNP,NNP,NN,VBZ,VBN,DT,NN,CD,NN,NN,.}","{3,3,5,5,0,11,11,11,11,5,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_83,"Received in formalin is a 1.7 x 1.0 X 0.5 cm anthracotic lymph node .","{Received,in,formalin,is,a,1.7,x,1.0,X,0.5,cm,anthracotic,lymph,node,.}","{receive,in,formalin,be,a,1.7,x,1.0,x,0.5,cm,anthracotic,lymph,node,.}","{VBN,IN,NN,VBZ,DT,CD,CC,CD,NN,CD,NN,JJ,NN,NN,.}","{6,0,1,6,6,0,0,11,11,9,6,14,14,11,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_84,"The entire specimen is sectioned and submitted in cassette B1 labeled C. Container C is labeled level 5 lymph node .","{The,entire,specimen,is,sectioned,and,submitted,in,cassette,B1,labeled,C.,Container,C,is,labeled,level,5,lymph,node,.}","{the,entire,specimen,be,section,and,submit,in,cassette,b1,label,C.,Container,C,be,label,level,5,lymph,node,.}","{DT,JJ,NN,VBZ,VBN,CC,VBN,IN,NN,NN,VBN,NNP,NNP,NNP,VBZ,VBN,NN,CD,NN,NN,.}","{3,3,5,5,0,0,5,0,10,5,10,14,14,16,16,11,21,21,21,10,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_85,"Received in formalin is a 1.2 x 0.8 x 0.6 cm red-tan lymph node .","{Received,in,formalin,is,a,1.2,x,0.8,x,0.6,cm,red-tan,lymph,node,.}","{receive,in,formalin,be,a,1.2,x,0.8,x,0.6,cm,red-tan,lymph,node,.}","{VBN,IN,NN,VBZ,DT,CD,CC,CD,CC,CD,NN,NN,NN,NN,.}","{6,0,1,6,6,0,0,6,0,11,6,14,14,11,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_86,"The lymph node is trisecled and i cassette C1 labeled","{The,lymph,node,is,trisecled,and,i,cassette,C1,labeled}","{the,lymph,node,be,trisecle,and,i,cassette,c1,label}","{DT,NN,NN,VBZ,VBN,CC,FW,NN,NN,VBN}","{3,3,5,5,0,0,5,9,7,9}","{}"
TCGA-55-7913, TCGA-55-7913SENT_87,"A. Ad_ditio __ n_als_ections 01 : tyg3_qH pleura are submitted in casse_ttes 1 _ ? l_S9 / ~ _ A1/Zylgla/elfe ?","{A.,Ad_ditio,__,n_als_ections,01,:,tyg3_qH,pleura,are,submitted,in,casse_ttes,1,_,?,l_S9,/,~,_,A1/Zylgla/elfe,?}","{a.,Ad_ditio,__,n_als_ections,01,:,tyg3_qh,pleuron,be,submit,in,casse_ttes,1,_,?,l_s9,/,~,_,a1/zylgla/elfe,?}","{NN,NNP,CD,NNS,CD,:,NN,NN,VBP,VBN,IN,NNS,CD,CD,CD,NN,:,CD,CD,NN,NN}","{2,4,4,0,10,0,8,5,10,4,0,10,14,12,16,14,18,4,21,21,18}","{}"
TCGA-55-7913, TCGA-55-7913SENT_88,"_ .","{_,.}","{_,.}","{NN,.}","{0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_89,"o * @ * Y * / .","{o,*,@,*,Y,*,/,.}","{o,*,@,*,y,*,/,.}","{NN,CD,SYM,CD,NN,CD,:,.}","{0,1,5,5,1,5,5,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_90,"_ M __ - _ .","{_,M,__,-,_,.}","{_,m,__,-,_,.}","{CD,NN,SYM,:,NN,.}","{0,1,5,0,1,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_91,"__ - .","{__,-,.}","{__,-,.}","{SYM,:,.}","{0,0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_92,"_ .","{_,.}","{_,.}","{NN,.}","{0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_93,"__ .","{__,.}","{__,.}","{NN,.}","{0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_94,".","{.}","{.}","{.}","{0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_95,"a _ .","{a,_,.}","{a,_,.}","{DT,NN,.}","{2,0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_96,"- ? - .","{-,?,-,.}","{-,?,-,.}","{:,NN,:,.}","{0,1,0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_97,"__ .","{__,.}","{__,.}","{NN,.}","{0,0}","{}"
TCGA-55-7913, TCGA-55-7913SENT_98,"_ @ *","{_,@,*}","{_,@,*}","{NN,SYM,SYM}","{0,1,1}","{}"
